〔Abstract〕 Objective To explore the application effect of human immunoglobulin combined with cefoperazone sodium and sulbactam sodium for injection in neonatal infectious pneumonia (NIP). Methods Forty NIP children admitted to Putian Children's Hospital from April 2021 to April 2022 were selected as research objects, and divided into a control group and an observation group by random number table method, with 20 cases in each group. The control group was treated with cefoperazone sodium and sulbactam sodium for injection, and the observation group was treated with pedestrian immunoglobulin combined with cefoperazone sodium and sulbactam sodium for injection. The disappearance time of clinical symptoms, serum inflammatory factor levels and therapeutic effect were compared between the two groups. Results (1) Disappearance time of clinical symptoms: dyspnea time, cough disappearance time, pulmonary rales disappearance time, temperature stability time, wheezing disappearance time of the observation group were shorter than those of the control group, the differences were statistically significant (P < 0.05). (2) Serum inflammatory factor levels: Before treatment, there were no significant differences in the levels of procalcitonin (PCT), C-reactive protein (CRP) and interleukin-6 (IL-6) between the two groups (P > 0.05); After treatment, the levels of serum inflammatory factors in the observation group were lower than those in the control group, and the differences were statistically significant (P < 0.05). (3) Treatment effect: The treatment effective rate of the observation group was higher than that of the control group, and the difference was statistically significant (P < 0.05). Conclusion The treatment of human immunoglobulin combined with cefoperazone sodium and sulbactam sodium for injection in children with NIP can effectively shorten the times of dyspnea, cough disappearance, pulmonary rales disappearance, temperature stability and wheezing disappearance of children, regulate the levels of serum inflammatory factors.